You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 8,057,807


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,057,807
Title:Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s): Schmidt; Richard A. (Arvada, CO)
Assignee: The Regents of the University of Colorado, a body corporate (Boulder, CO)
Application Number:12/243,659
Patent Claims:1. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a botulinum toxin to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction.

2. The method of claim 1, wherein the patient is a human.

3. The method of claim 1, wherein the patient is a human female.

4. The method of claim 1, wherein the patient is a human male.

5. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

6. The method of claim 1, wherein a symptom of the recalcitrant voiding dysfunction is urinary incontinence.

7. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a therapeutically effective amount of botulinum toxin type A to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction.

8. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is injected in the amount up to 2500 units.

9. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.

10. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

11. The method of claim 7, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

12. A method for treating a recalcitrant voiding dysfunction in a patient in need thereof, the method comprising the step of administering a botulinum toxin type A, in an amount of up to 2500 units, to a bladder wall of a patient with a recalcitrant voiding dysfunction, thereby treating the recalcitrant voiding dysfunction of the patient with a recalcitrant voiding dysfunction.

13. The method of claim 12, wherein the botulinum toxin type A is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, and a solution.

14. The method of claim 12, wherein administration of the botulinum toxin results in an increase in bladder capacity of the patient.

15. The method of claim 14, wherein bladder capacity is increased to about 300 to 400 cubic centimeters post-administration.

16. The method of claim 12, wherein the patient is a human.

International Patent Family for US Patent 8,057,807

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9903483 ⤷  Subscribe
United States of America 9066943 ⤷  Subscribe
United States of America 8840905 ⤷  Subscribe
United States of America 8062643 ⤷  Subscribe
United States of America 7968104 ⤷  Subscribe
United States of America 7470431 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.